SEC EDGAR 8-KNov 10$TLSI

TriSalus Life Sciences Reports Third Quarter 2026 Results

TriSalus Life Sciences, Inc. (TLSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. TriSalus Life Sciences Reports Third Quarter 2026 Results Generated third quarter revenue of $12.9 million, driven by expanded commercial organization and increasing market penetration Revised 2026 revenue guidance to $46 million to $48 million Centers for Medicare & Medicaid Ser

Original reporting

SEC EDGAR 8-K

Published Nov 10, 2026, 1:06 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 10, 2026, 1:08 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$TLSI

Bullish

medium confidence

Mentioned

$TLSI

Relevance

7/10

AlphAI data visualization · based on SEC EDGAR 8-K

Decision brief

The 30-second read

$TLSIBullishMed

Why it matters

The earnings beat and guidance revision may prompt short-term price appreciation, but long-term growth depends on adoption of PEDD technology.

Market read

First report of earnings and guidance update provides fresh data for traders.

What to watch

Potential reimbursement policy changes could affect future revenue more than current guidance.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

TriSalus Life Sciences reported Q3 2026 results, including FDA clearance for TriNav Advance and updated revenue guidance.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TLSIBullishMedium confidence

Context

TriSalus updated its full-year 2026 revenue guidance to $46M-$48M, up from prior expectations.

Expected impact

likely modest upside as market prices in higher revenue outlook

Evidence & confidence

The updated guidance reflects 2-6% growth and better gross margins, which may attract buyers.

Market effects

Sector

May boost sentiment in the medical technology and oncology device sector.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact beyond niche biotech space.

Counterpoint

What could challenge this read

Guidance increase is modest; investors may view it as insufficient given high valuation.

Key entities

company
TriSalus Life Sciences
Oncology-focused medical technology firm.
executive
Mary Szela
President and CEO of TriSalus.

Read at source ← All news

$TLSIHigh

TriSalus Life Sciences Reports 11.3% Q3 Revenue Growth to $12.9 Million, Revises 2026 Guidance

TriSalus Life Sciences (TLSI) reported Q3 2026 revenue of $12.9M, up 11.3% YoY, and revised 2026 guidance to $46M-$48M. Gross margin improved to 86.2%, and operating losses narrowed. The company received FDA clearance for TriNav Advance and expects higher Medicare reimbursement rates. CEO Mary Szela cited commercial growth but noted slower sales rep productivity. Cash reserves stood at $41.1M post-equity offering.

finance.yahoo.comNov 10

$MESOHighAI 9/10

Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study

Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.

rttnews.comSep 25

$TLSIHighAI 8/10

Why is TriSalus Life Sciences stock surging today?

TriSalus Life Sciences (TLSI) stock rose 15.6% in pre-market trading after FDA clearance for its TriNav Advance device, which expands its drug delivery portfolio. The device enables delivery to small vessels and supports two operating modes. CEO Mary Szela highlighted its role in enhancing the company's offerings. The rally is driven by company-specific news, with no significant market tailwinds.

investing.comSep 23

$WORHigh

Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

Worthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.

benzinga.comSep 23

$TLSIHighAI 9/10

TriSalus Life shares surge 29% on FDA device clearance

TriSalus Life Sciences (TLSI) shares rose 29% after receiving FDA 510(k) clearance for TriNav Advance, a new device for its Pressure-Enabled Drug Delivery portfolio. The device expands access to small, distal vessels and supports a broader range of embolization procedures. The company plans a limited market release soon. According to the company, the device enhances its portfolio and enables physicians to optimize therapeutic delivery in complex cases.

investing.comSep 22